XML 165 R110.htm IDEA: XBRL DOCUMENT v3.6.0.2
Collaborative and Other Relationships (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Revenues from unconsolidated joint business                      
Revenue on sales in the rest of world for RITUXAN $ 2,502.9 $ 2,539.6 $ 2,466.0 $ 2,309.4 $ 2,425.9 $ 2,391.7 $ 2,198.6 $ 2,172.3 $ 9,817.9 $ 9,188.5 $ 8,203.4
Total revenues from anti-CD20 therapeutic programs $ 318.2 $ 317.6 $ 349.2 $ 329.5 $ 333.9 $ 337.2 $ 337.5 $ 330.6 1,314.5 1,339.2 1,195.4
U.S                      
Revenues from unconsolidated joint business                      
Revenue on sales in the rest of world for RITUXAN                 7,050.4 6,545.8 5,566.7
Total revenues from anti-CD20 therapeutic programs                 1,249.5 1,269.8 1,117.1
Roche Group - Genentech                      
Revenues from unconsolidated joint business                      
Total revenues from anti-CD20 therapeutic programs                 1,314.5 1,339.2 1,195.4
Roche Group - Genentech | U.S                      
Revenues from unconsolidated joint business                      
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses                 $ 1,249.5 1,269.8 1,117.1
GAZYVA                      
After First GA101 Threshold Date                      
Until First GAZYVA Threshold Date 39.00%               39.00%    
After First Threshold Date and until Second Threshold Date 37.50%               37.50%    
After Second Threshold Date 35.00%               35.00%    
RITUXAN                      
Co-promotion profit sharing formula                      
Until GAZYVA First Non-CLL FDA Approval 40.00%               40.00%    
After First GA101 Threshold Date                      
Until First GAZYVA Threshold Date 39.00%               39.00%    
After First Threshold Date and until Second Threshold Date 37.50%               37.50%    
After Second Threshold Date 35.00%               35.00%    
RITUXAN | Roche Group - Genentech | Outside the U.S                      
Revenues from unconsolidated joint business                      
Revenue on sales in the rest of world for RITUXAN                 $ 65.0 $ 69.4 $ 78.3